Related by context. All words. (Click for frequent words.) 90 Receives FDA Clearance 88 FDA Clears 88 Gets FDA Clearance 84 Announce License Agreement 83 Completes Enrollment 83 Receives Orphan Drug Designation 83 Completes Patient Enrollment 83 Files IND 82 Begins Shipment 82 FDA Approvals 82 Introduces Revolutionary 81 Awarded Patent 81 Files Patent Application 81 Receives Patent 81 Initiates Enrollment 81 FDA Okays 81 Sign Licensing Agreement 81 Receives Approvable Letter 81 Receives CE Marking 81 Introduces Next Generation 81 Submits NDA 81 Initiates Clinical Trial 80 Sign License Agreement 80 Enrolls First 80 FDA Clearance 80 Receives CE 80 Announce Collaboration Agreement 79 Commercializes 79 Licenses Novel 79 Initiates Clinical Trials 79 Announce Licensing Agreement 79 Significantly Improves 79 Awarded Patents 79 Receives Milestone Payment 79 Initiates Phase II 79 Patent Issued 79 Announce Merger Agreement 78 ORLive Presents 78 Obtains FDA 78 Introduces Enhanced 78 Demonstrates Significant 78 Unveils Revolutionary 78 Introduces Breakthrough 78 Develop Novel 78 Announces Immediate Availability 78 Announces Licensing Agreement 78 Introduces Novel 78 Announces License Agreement 78 Develop Next Generation 78 Significantly Reduces 78 Settle Patent Litigation 78 Delivers Next Generation 78 Study Demonstrates 78 Presents Preclinical Data 77 Signs License Agreement 77 Submits Application 77 Unveils Next Generation 77 Achieves Milestone 77 Introduces Innovative 77 Initiates Clinical 77 Begins Shipping 77 Strengthens Position 77 Launches Next Generation 77 FDA Approves 77 Improves Survival 77 Releases Next Generation 77 Reduces Risk 77 Receives SFDA Approval 77 Presents Positive 77 Signs Licensing Agreement 77 Unveils Groundbreaking 76 Obtains Exclusive License 76 Demonstrates Potential 76 Patient Enrollment 76 Expands Portfolio 76 Announces Initiation 76 Drug Candidate 76 Finalizes Acquisition 76 Expand Collaboration 76 Announces Successful Completion 76 Submits IND 76 Expands Capabilities 76 Less Invasive 76 Named Exclusive Distributor 76 Unveils Innovative 76 Non Invasive Treatment 76 Settle Patent Dispute 76 Vascular Grafts 76 Completes Tender Offer 76 IND Application 76 Shows Promise 76 Shows Promising 76 Receives Favorable 76 Settles Patent Dispute 76 Meets Primary Endpoint 75 Absorbable 75 Taro Receives 75 Clinical Trial Evaluating 75 Provides Update Regarding 75 Announces Tentative Approval 75 Announces Enhancements 75 Expanded Indication 75 Therapeutic Competitors Companies 75 includes Dideco CarboMedics 75 Commences Phase 75 Granted Orphan Drug 75 Announce Availability 75 Completes Merger With 75 First Patient Treated 75 Files Patent 75 Clinical Study Shows 75 Showcases Innovative 75 Develops Innovative 75 Significantly Increases 75 k Clearance 75 Initiates Dosing 75 REMINDER ORLive Presents 75 AnaSpec Introduces 75 Acquires Exclusive 75 Receives Orphan Drug 75 Secures Financing 75 Proves Successful 75 Issued Patent 75 Clinical Trial Results 75 Drug Shows Promise 75 Achieves Primary Endpoint 75 Successfully Completes Tender Offer 75 Successfully Treats 75 Embolic Protection 75 Completes Installation 75 Announce Collaboration 75 Achieves ISO #:# Certification [002] 75 Extends Collaboration 75 Proven Effective 75 Nasdaq SMTS develops manufactures 75 Improves Quality 75 Taglich Brothers Initiates Coverage 75 Receives Clearance 75 Initiate Clinical Trial 75 Wins Patent Infringement 75 Present Preclinical Data 75 Launches Generic Version 75 Jumps Higher 75 Initiates Voluntary Recall 75 Receives Tentative Approval 74 Secures Patent 74 Submits Biologics License Application 74 Improves Outcomes 74 Dramatically Increases 74 Successfully Tests 74 Contrast Agent 74 Flagship Product 74 Demonstrates Positive 74 Sinks Lower 74 Q1 Loss Narrows 74 Amends Agreement 74 Completes Divestiture 74 Announces Publication 74 Introduces Unique 74 Veeco Introduces 74 Announces Favorable 74 Hematology Molecular Pathology 74 Q2 Loss Narrows 74 Non Invasive 74 Announces Divestiture 74 Ships #th 74 Submits Response 74 Cypher Sirolimus 74 Inks Licensing Deal 74 Introduces Powerful 74 Announce Definitive Agreement 74 Vascular Graft 74 FDA Accepts 74 Reveals Positive 74 Drug Eluting Coronary Stent 74 Launches Innovative 74 Launches Enhanced 74 Unveils Latest 74 Achieves Significant 74 Receives Notification 74 Obtains License 74 Successfully Tested 74 Develop Innovative 74 Successfully Concludes 74 Acquires Assets 74 Device Maker 74 Strengthens Balance Sheet 74 Improves Efficiency 74 Q4 Loss Narrows 74 Shows Promise Against 74 PROMUS TM 74 Expands Availability 74 Receives Regulatory 74 Completes Successful 74 Obtains Approval 74 Bioresorbable 74 Acquire Assets 74 Enters Into License Agreement 74 Q3 Loss Narrows 74 Obtains CE Mark 74 Adjuvant Treatment 73 Further Validates 73 Successfully Completes 73 Cerebral Somatic Oximeter 73 Carotid Stent 73 Introduces Affordable 73 Announces Issuance 73 Patent Covering 73 Provides Comprehensive 73 Reduces Pain 73 Subsidiary Enters 73 Prolongs Survival 73 Enters Into Exclusive 73 Begins Dosing 73 Study Evaluating 73 Announces Presentation 73 Q3 Loss Widens 73 Effectively Treats 73 Strengthens Leadership 73 Achieves Certification 73 Releases Enhanced 73 Successfully Completes Phase 73 Reports Positive 73 Test Detects 73 Mylan Receives Approval 73 BioSante Pharmaceuticals Announces 73 FDA Warns 73 Receives Fast Track 73 Provide Comprehensive 73 Receives Certification 73 Buy Privately Held 73 Syneron logo 73 Patients Undergoing 73 Files Shelf Registration Statement 73 Enters Into Licensing Agreement 73 Boosts Productivity 73 Minimally Invasive Procedure 73 Drug Fails 73 Announces Definitive Agreement 73 PRN FDA Approves 73 Microwave Ablation System 73 Receives Funding 73 Acquire Privately Held 73 Receives Positive 73 Generic Version 73 Teva Provides Update 73 Pivotal Study 73 Voluntarily Withdraws 73 Molecular Diagnostic Test 73 Explore Strategic Alternatives 73 Equipment Deals 73 Provides Shareholder 73 Launches Unique 73 Initiates Phase III 73 Generic Versions 73 Enhances User Experience 73 Unveils Newest 73 Therapeutic Competitors Report 73 Patients Treated With 73 Novel Oral 73 Phase 2b Clinical Trial 73 Restructures Debt 73 Delivers Breakthrough 73 Presents Positive Preclinical 73 Reports Preclinical Data 73 Board Authorizes 73 Receives Favorable Ruling 73 Helps Predict 73 Completes Merger 73 Jointly Announce 73 Signs Merger Agreement 73 Doubles Capacity 73 Unveils Expanded 73 Spinal Implant 73 Immunomedics Announces 73 Develops Breakthrough 73 Single Dose 73 endoscopic autofluorescence imaging 73 Preclinical Data 73 Phase III Clinical Trial 73 AUDIO PROVIDED BY 73 Launches Redesigned Website 73 Announces Stockholder Approval 73 Contrast Enhanced 73 Unveils Breakthrough 73 Files Patents 73 Introduces Expanded 73 injectable bulking agent 73 Image Guided 72 Rheumatoid Arthritis Drug 72 Thoracic Endoprosthesis 72 Restructures Operations 72 Could Revolutionize 72 Successfully Completed 72 Treatment Reduces 72 Secures Additional 72 Settle Litigation 72 Q2 Loss Widens 72 Milestone Payment 72 Successfully Deploys 72 Demonstrates Interoperability 72 Achieves ISO # 72 Announces Additions 72 Receives NASDAQ 72 Expands Scope 72 Announces Positive 72 Study Shows Benefits 72 Completes Integration 72 Mutually Agree 72 Completes Expansion 72 Pivotal Clinical Trial 72 Discontinues 72 Completes Acquisitions 72 Debuts Next Generation 72 Arthritis Drug 72 Eliminates Need 72 Collaborators Present 72 Licenses Patents 72 Unveils Upgraded 72 Board Unanimously Rejects 72 Achieves Breakthrough 72 Extends Capabilities 72 Regains Compliance With 72 Broadens Its 72 Files Patent Infringement 72 Settles Litigation 72 Announces Adjournment 72 Patients Enrolled 72 Completes Purchase Of 72 Transdermal Patch 72 Reacquires 72 Extend Partnership 72 Welcomes Analyst Initiation 72 Awarded Qualifying Therapeutic 72 Announces Organizational Changes 72 Proudly Announces 72 Enters Agreement 72 Earns Milestone Payment 72 Awarded GSA Schedule 72 Psoriasis Drug 72 Successfully Treated 72 Announces Voluntary Recall 72 Commercialize 72 Successfully Demonstrates 72 Announce Receipt 72 Vitrasert R 72 NDA Submission 72 Receives Unsolicited 72 Settles Patent Litigation 72 Strengthens Its 72 Appoints Experienced 72 Receives Positive Opinion 72 Obtains Exclusive Rights 72 Updates Guidance 72 Ablation System 72 CONFERENCE CALLS SOURCE 72 Begins Clinical Trial 72 Shareholders Approve Acquisition 72 Achieves Record Sales 72 Announces Commencement 72 Phase III Trial 72 Demonstrates Latest 72 Launches Groundbreaking 72 Tissue Engineered 72 Phase 2b Trial 72 Successfully Completes Acquisition 72 Completes Transition 72 Earnings Postmortem 72 Drug Eluting 72 Initiate Phase III 72 Develops Novel 72 vapreotide acetate 72 Announces Rebranding 72 Regains NASDAQ 72 Balloon Catheters 72 Announces Poster Presentations 72 Achieves Positive 72 Reports Receipt 72 Acquires Controlling Interest 72 Expands Capacity 72 Secures Funding 72 Canaccord Genuity Reiterates Buy 72 Mitral Valve Repair 72 Q4 Loss Widens 72 Provides Guidance 72 Regains Compliance 72 Osteoporosis Treatment 71 Lowers Risk 71 Antimicrobial Coating 71 Terminate Merger Agreement 71 Identifies Potential 71 3M Completes Acquisition 71 Extends Tender Offer 71 Announces Effective Date 71 Further Strengthens 71 PROMUS R 71 Patient Treated 71 Completes Reorganization 71 Announces Termination 71 TM Everolimus Eluting 71 Guides Inline 71 TM Embolic Protection 71 Holds Promise 71 Expand Relationship 71 Bullish Engulfing Pattern 71 Confirms Commitment 71 Announce Licensing 71 Expands Functionality 71 Presents Preclinical 71 Introduces Groundbreaking 71 Finalizes Purchase 71 First Patient Enrolled 71 Slows Progression 71 FDA Panel Recommends 71 Collaborators Publish 71 Signs Agreements 71 Nicotine Vaccine 71 Pulmonary Valve 71 Spinal Fusion 71 Ramps Up Production 71 Collaborates With 71 Oral Mist 71 Releases Latest Version 71 Renews Agreement 71 Revolutionizes 71 PRODUCT SOURCE 71 platform HDL Mimetic 71 Receives Complete Response 71 Planned Acquisition 71 Increases Productivity 71 Proves Effective 71 COMUNICADO 71 Platform Enables 71 Helps Detect 71 Introduces Newest 71 Lupus Drug 71 Licensing Pact 71 Demonstrates Commitment 71 Curon Control 71 Reconfirms 71 Extend Collaboration 71 Patent Infringement Lawsuit 71 PRN8 71 Completes Buyout 71 Eur J 71 Platinum Chromium 71 Prostate Cancer Vaccine 71 Announce Expanded 71 Drug Coated Stent 71 Announces Availability 71 Unveils Enhanced 71 PerkinElmer Acquires 71 Offers Unprecedented 71 Announces Dismissal 71 Significantly Enhances 71 Receives Conditional 71 Osteoporosis Drug 71 ANADIGICS Announces 71 CysDisplay R 71 Q1 Loss Widens 71 Phase IIb Clinical Trial 71 Delivers Enhanced 71 Receives Approval 71 Shareholders Approve Merger Agreement 71 TM Aganocide 71 Recall Issued 71 Completes Reverse Merger 71 Dry Powder Inhaler 71 Successfully Integrates 71 Q2 Adj 71 ™ Paclitaxel Eluting 71 Regenerative Cell 71 Phase 2a Trial 71 Receives Subpoena 71 NAVISTAR R 71 Blood Thinner 71 Pivotal Trial 71 Toshiba Develops 71 Stockholders Approve Acquisition 71 Effective Than 71 Balloon Catheter 71 Successfully Demonstrate 71 TM Drug Eluting 71 Successfully Launches 71 Lowers Guidance 71 Misonix Announces 71 Streamlines Operations 71 Commercially Available 71 PAUL Minn.MN 71 Device Helps 71 WorldHeart Announces 71 Obtains Patent 71 Exploring Strategic Alternatives 71 Prove Effective 71 Announce Expiration 71 Verisyse TM intraocular lenses 71 Migraine Drug 71 Expands Relationship With 71 Completes Initial 71 Announce Settlement 71 Delivers Improved 71 Receives Accreditation 71 Crit Rev 71 Forward Looking IVUS 71 Pharmaceuticals Initiates 71 Successfully Closes 71 Announces Expanded 71 Receives Notice 71 Demonstrates Ability 71 Achieves SAS 71 Phase IIb Trial 71 Motorola Invests 71 Phase 1b Clinical Trial 71 Announce Reseller Agreement 71 Q1 Adj 71 Combination REOLYSIN R 70 FY# Loss Widens 70 Anti Tumor Activity 70 TRANSDUR ® 70 Genotyping Test 70 Thrombectomy System 70 Delivers Unprecedented 70 Slow Progression 70 Systemic Delivery 70 Reduces Debt 70 Spins Out 70 Evaluate Strategic Alternatives 70 Investigational Compound 70 Receives Commitment 70 Improves Patient 70 Jointly Develop 70 Gets Clearance 70 Develops Next Generation 70 Carotid Stent System 70 Commercialize Novel 70 Software Simplifies 70 Bone Metastases 70 Accelerate Commercialization 70 Becomes Exclusive Distributor 70 Offers Affordable 70 Attrius ™ PET 70 Bearish Speculation 70 Announces Successful 70 Lifts FY# Outlook 70 Enters Definitive Agreement 70 Extends Reach 70 Heart Failure Patients 70 Patients Treated 70 MONSTERSTOX.COM Monsterstox.com 70 Patent Lawsuit 70 Host Teleconference 70 Announces Launch 70 Completes Recapitalization 70 Therapy Improves 70 Dual Wavelength 70 Doubles Size 70 Continues Aggressive 70 Investigational Treatment 70 Announce Commencement 70 Commences Tender Offer 70 Provides Preliminary 70 Enters Into Agreement 70 Restate Financials 70 Demonstrates Statistically Significant 70 Gliadel R 70 FDA APPROVES 70 Helps Prevent 70 Breast Biopsy 70 Therapy Reduces 70 Settles Patent Suit 70 Successfully Installs 70 Terminates Contract 70 Being Studied 70 Finalizes Sale 70 Regenerative Cells 70 Kidney Transplant Patients 70 Completes Previously Announced 70 Guidelines Issued 70 Starts Shipping 70 Files Investigational 70 Expands Internationally 70 Diagnostic Tests 70 Patent Infringement Suit Against 70 Confirms Receipt 70 Advanced Melanoma 70 hc2 High Risk 70 Gout Drug 70 Announces Early Termination 70 MSON 70 received CE Conformité 70 Flamel Technologies Announces 70 Awarded Multi 70 products visit www.#M.com/touch# 70 Subsidiary Receives 70 Appears Safe 70 Q3 Profit Decreases 70 Gene Expression Analysis 70 Consummates 70 Extends Leadership 70 liver resection surgeries 70 Voluntarily Withdraw 70 Phase 2a Clinical Trial 70 Announce Initiation 70 Announces Definitive Agreements 70 Implantable Device 70 Altera Ships 70 MicroFuse R 70 Announces Signing 70 Submits Supplemental 70 Q1 Profit Surges 70 Study Validates 70 Vaccine Adjuvant 70 INTELLITEMP ® 70 Closes Acquisition Of 70 Cell Transplants 70 Protects Against 70 Thewallstreetleader.com Profiles 70 Expands Distribution 70 Cites Positive 70 FDA Approval 70 Completes Acquisition 70 AMPLATZER R 70 Enhances Functionality 70 Inks Distribution 70 Breast Cancer Recurrence 70 Voluntarily Recalls 70 Intravascular 70 Evalve MitraClip R 70 Intraocular Lens 70 Releases Latest 70 Study Shows Significant 70 Fortifies 70 Blood Pressure Drug 70 Achieves Highest 70 Amend Merger Agreement 70 Cardiac Rhythm 70 HER2 Positive 70 Showcases Next Generation 70 Retains CCG Investor Relations 70 Closes Acquisition 70 Receives Authorization 70 RNA Amplification 70 HuCAL PLATINUM R 70 Distribution Pact 70 IND Filing 70 Cardiovascular Prosthetic Devices 70 Enters Into Strategic 70 Phase IIa Clinical Trial 70 Helps Identify 70 Terminates Merger Agreement 70 Sign Definitive Agreement 70 Anti Nausea 70 Tyrosine Kinase Inhibitor 70 visit http:/www.mannkindcorp.com 70 PATHFINDER R 70 Cervical Imaging 70 Closes Merger 70 COMPLETES ACQUISITION OF 70 & Sullivan Recognizes 70 Miraculins Announces 70 CORTOSS R 70 For Undisclosed Terms 70 siRNA Delivery 70 Shown Effective 70 Revises FY# Outlook 70 Fungal Infections 70 Clinical Outcome 70 Novel Compound 70 Closes Sale 70 DuraGen Plus 70 BIOLASE Announces 70 Achieves Record 70 External Beam 70 Achieves Unprecedented 70 Eases Pain 70 BioElectronics Announces 70 Announces Postponement 70 Uracyst R Test 70 Significantly Improved 70 PerkinElmer Introduces 70 Attains 70 Reports Profitable 70 candidates Azedra TM 70 Contrast Agents 70 Diabetic Foot Ulcer 70 High Growth Forecasted 70 Extends Maturity 70 PATHFINDER ® TRACER 70 Announces Discontinuation 70 Announces Ticker Symbol 70 BioElectronics Corporation Announces 70 Antitumor Activity 70 Complete Merger 70 Significantly Expands 70 Dramatically Expands 70 Receives Order 70 Investigational Oral 70 Revises Guidance 70 Patent Infringement Lawsuit Against 70 Acquire Controlling Interest 70 Amplifies 70 SABER ™ 70 visit www.dobimedical.com 70 Announces Completion 70 Molecular Mechanism 70 Announces Formation 70 Liberte TM 70 Receives ISO #:# [001] 70 Cholesterol Lowering Drug 70 Plaque Psoriasis 70 Insulin Pen 70 PRN2 70 Enters Oversold Territory 70 Successfully Complete 70 Newly Identified 70 Narrows Guidance 69 Initiates Phase 69 Technicals Showing Bearish 69 Expands Commitment 69 Deliver Powerful 69 INVOS R 69 Interferon Alpha 69 Completes Purchase 69 INDUSTRY ASSESSMENTS 69 Synthetic Peptide 69 pralatrexate injection folate analogue 69 Provides Unprecedented 69 Nanophase Announces 69 Stockholders Approve Merger 69 Extend Relationship 69 Shows Statistically Significant 69 Signs Reseller Agreement 69 Bullish Average Crossover 69 Patents Covering 69 STERIS Corporation Announces 69 Celebrates Opening 69 Achieves ISO 69 Announce Early Termination 69 Study Confirms 69 Cholesterol Drug 69 Could Save Lives 69 Earns Certification 69 Formalizes 69 Neurosurg 69 Product Offerings 69 Zicam Cold Remedy RapidMelts 69 Derma Sciences Announces 69 Receives ISO #:# [002] 69 MarketsandMarkets Global 69 SIX RO ROG 69 ATS Simulus R 69 Data Suggest 69 Improve Survival 69 PPD Declares 69 Demonstrates Next Generation 69 Attracting Bullish Investors 69 Completes Asset 69 Shows Efficacy 69 Expands Scientific Advisory 69 Helps Reduce 69 Drug Prevents 69 Q3 Adj 69 Transdermal Drug 69 #-# Full Text 69 Receive Milestone Payment 69 Patent Infringement Litigation 69 Oral Calcitonin 69 Confirms Efficacy 69 Study Indicates 69 Imaging Technique 69 TAXUS Element Paclitaxel Eluting 69 INTELLITEMP ® Energy 69 Complicated Skin 69 Updates Status 69 ODT metoclopramide HCl PEPCID 69 Q4 Profit Surges 69 markets COLAZAL 69 IG HCR ;) CO 69 Vascular Closure Device 69 Dural Regeneration Matrix 69 Study Casts Doubt 69 Kinase Inhibitor 69 REPRONEX R menotropins 69 Agilent Technologies Introduces 69 Receives Approvals 69 Provides Updates 69 FDA Approves Drug 69 Introduce Next Generation 69 candidates Azedra 69 Demonstrate Latest 69 Receives Coveted 69 Q2 Profit Surges 69 Injectable Gel 69 Ups Guidance 69 Robotic Catheter System 69 R MSCRAMM 69 Deliver Innovative 69 Improves Accuracy 69 Expands Offerings 69 Guides FY# Update 69 Completes Dosing 69 Peripherally Inserted Central 69 Completes Sale 69 Initiates Voluntary 69 Tumor Targeting 69 JAK2 Inhibitor 69 NewsBite Downgrade Puts Pressure 69 Anticancer Drug 69 Scientists Develop 69 License Pact 69 researches develops licenses 69 Subsidiary Acquires 69 Milestone Achieved 69 Broadens Scope 69 Buys Majority Stake 69 Bullish Speculation 69 Edwards SAPIEN 69 Announce Launch 69 Hip Prosthesis 69 Announces Underwriters Exercise 69 Crofelemer budesonide foam 69 Announces Sponsorship 69 lead molecular radiotherapeutic 69 Can Detect 69 Announces Cancellation 69 Mg Usa 69 Regains Nasdaq 69 Inc Therapeutic Competitors 69 Files Registration Statement 69 ™ Everolimus Eluting 69 Solution Enables 69 Announces Recapitalization 69 Embolic 69 Initiates Phase 2b 69 Jointly Offer 69 Manufacturer Selects 69 Patent Infringement Suit 69 CE marked PROGENSA 69 Robotic Assisted 69 Peripheral Arterial 69 Daytradersdigest.com 69 Offers Enhanced 69 Demonstrates Superior 69 Significantly Reduced 69 ΞΕΝΗ ΔΗΜΟΣΙΕΥΣΗ ΑΝΑΚΟΙΝΩΣΗInfosys Finacle 69 MEDW 69 Therapeutic Competitors companiesandmarkets.com adEgemonye 69 Unsolicited Proposal From 69 Introduces Redesigned 69 Unveils Latest Version 69 Inc. OTCBB CADM 69 Issues Guidance 69 Achieves Prestigious 69 R famotidine 69 FY# Loss Narrows 69 Broadens Product 69 Small Molecule 69 Enters Into Definitive Agreement 69 Net Loss Widens 69 Inhaled Nitric Oxide 69 Transdermal Delivery 69 Outlines Strategy 69 Sirolimus Eluting Stent 69 MR Angiography 69 Announcement acc 69 Could Detect 69 Custom NX R 69 Announce Completion 69 Study Evaluates 69 Bearish MACD 69 Infusion Pumps 69 Asthma Treatment 69 Cuts Costs 69 Cholesterol Lowering 69 Delivers Powerful 69 proprietary radiolabeled monoclonal 69 Talent Abdominal 69 AllPennyStocks.com Spotlights 69 AGREEMENTS SOURCE 69 Net Loss Narrows 69 Record Third Quarter 69 Patent Lawsuit Against 69 Reduces Cost 69 Awarded Prestigious 69 SilverHawk System 69 Novartis Novo Nordisk 69 Receives Notice From 69 Successfully Demonstrated 69 TriCo Bancshares Announces 69 Q4 Profit Plunges 69 Rated Speculative Buy 69 CybeRelease Decliners 69 Differentiates 69 Measurement Instruments 69 Drug Eluting Stent 69 Treating Chronic 69 Celebrates Decade 69 Wins Approval 69 Sign Reseller Agreement 69 Severe Sepsis 69 Momentum Continues 69 Bush Embraces Pause 69 Lung Cancer Drug 69 Announces Addition 69 Spins Off 69 Reports Significantly Improved 69 VIVUS Announces 69 TRADESHOW SOURCE 69 Expands Deployment 69 Femtosecond Laser 69 Commenced Against 69 Posts 4Q 69 Bearish Average Crossover 69 Glaucoma Treatment 69 Baerveldt R 69 Showcases Latest 69 COMUNICADO DE 69 Reaffirms Outlook 69 Retains Leading 69 Pulse Oximetry 69 Announce Agreement 69 Reduces Size 69 Enables Easy 69 Host Fourth Quarter 69 INDICATED LOWER 69 Announce Exclusive 69 Receives Recognition 69 Trial Evaluating 69 BIOTECHNOLOGY SOURCE 69 Appoints Seasoned 69 Delivers Unparalleled 69 Announces Affiliation 69 Selects Camstar 69 Celebrates Successful 69 Reduces Mortality 69 Medical Sorin Biomedica 69 Demonstrates Innovative 69 Stent Coating 69 PRN1 69 Withdraws Application 69 Provides Updated 69 Terminates Agreement 69 Aloxi ® 69 ATRA IV 69 Posts Wider Loss 69 Obtains FDA Clearance 69 Finalize Agreement 69 DayTradersDigest.com Profiles 69 Secures Contract 69 Announces Receipt 69 Preclinical Study 69 Closes Previously Announced 69 Executes Agreement 69 R Saizen R 69 Heart Stents 69 Spectrum Pharmaceuticals Announces 69 Immunoassay Systems 69 Eluting Stent 69 Files Voluntary 69 Circulating Tumor Cells 69 Protein Synthesis 69 Posts Wider 69 Changes Ticker Symbol 69 Using Dip Pen 69 Relocates Corporate Headquarters 69 & Sullivan Lauds 69 Bullish Technical Alert 69 Exercises Option 69 Accelerates Growth 69 ® VAD Ventricular 69 Generic Version Of 69 Adsorbent 69 Strengthens Commitment 69 Achieves Milestones 69 Increases Risk 69 Prostate Cancer Treatment 69 Cardiac Mapping 69 Study Proves 69 Wafer polifeprosan 69 Gets Approval 69 Guidelines Recommend 69 Demonstrate Innovative 69 Confirmatory Phase 69 Delivers Comprehensive 69 Reaffirms FY# Outlook 69 Contaminant Found 69 TRANSDUR ™ 69 Announces Expansion 69 PRN3 69 Inks Pact 69 Reschedules Fourth Quarter 69 Other OTC MNDP 69 Results Confirm 69 Proc Am Soc 68 visit www.genenews.com 68 Inks License 68 Treatment Shows Promise 68 Novel Compounds 68 Milestone Payment From